Multidrug-Resistant Organisms in ICU: Infections, Diagnosis, Prevention

by

Multidrug-resistant organisms (MDROs) are well established and raise growing public health concerns, as few therapies remain when they are exposed to multiple antibiotics, increasing antibiotic resistance among bacteria.

Though many whole antimicrobial antibiotics are in use, phenomenally, only a few antibiotics are available for the treatment of them. Mostly, considering severe nosocomial infections like ventilator-associated pneumonia, Klebsiella pneumonia, etc., escalating the mortality rate, hospital stay, and healthcare costs. The World Health Organization names multidrug-resistant organisms as one of the top global public health threats.

Multidrug-Resistant Organisms in ICU
Multidrug-Resistant Organisms in ICU

Epidemiology and Burden of Multidrug-Resistant Organisms Infections in ICU

The rates of multidrug-resistant Gram-positive bacteria vary across different parts of the world. In Europe, there is quite a bit of variation between countries, with MRSA rates ranging from less than 1% up to over 50%. The list of general MRSA is rare in the northern countries and more common in the south and Europe, but some regional differences are still not fully understood. The highest rates were seen in Portugal, 49%. Greece (40%) and Italy (37%) are the lowest in Norway (less than 1%), Sweden (1%), and the Netherlands (1%). Interestingly, in 2008, most countries experienced a decrease in MRSA for the first time ever, reversing the previous upward trend. 

Negative bacteria multidrug resistance is a major threat to humanity, especially the patients admitted to the ICU. The prevalence of multidrug-resistant Gram-negative bacteria was found to be 83.15% susceptible to commonly used oral and intravenous antibiotics, which was low out of 380 Gram-negative bacteria. Multi-drug-resistant bacteria like Acinetobacter species 43, non-fermenter 57, and E. coli 129 were resistant to the carbapenem group of antibiotics. Acinetobacter species can survive in the environment for a long period of time, even in dry conditions on particles and dust, which causes the rapid dissemination of multiple drug resistances.

Common Multidrug-Resistant Organisms in ICU Settings

ICU is a major battleground for antimicrobial resistance. In recent decades, the paradigm has shifted from Gram-positive pathogens to highly resilient Gram-negative ‘superbugs.’ The most serious threats are often abbreviated as ESKAPE:

Gram-Negative Pathogens

Klebsiella pneumoniae (especially carbapenemase-producing strains, or KPC-KP), Acinetobacter baumannii, Pseudomonas aeruginosa, and extended-spectrum β-lactamase-producing Escherichia coli. Acinetobacter is highly notorious in ICUs, frequently causing ventilator-associated pneumonia.

Gram-positive pathogens

Although the incidence of these pathogens has plateaued, Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus (VRE) remain an ominous threat to critically ill patients.

Mechanisms of Antimicrobial Resistance in Multidrug-Resistant Organisms

Bacteria don’t just survive antibiotics. They dodge them with brilliant evolutionary defense strategies. Generally, these survival mechanisms are divided into four types:

  • Enzymatic Inactivation (Deactivates drug, e.g., β-lactamases)
  • Efflux Pumps (actively pump the antibiotic out)
  • Structural Change (Changes target site so drug cannot bind)
  • Reduces permeability (Shuts porin channels to block entry)

Bacteria can acquire these traits through random genetic mutations or through horizontal gene transfer (HGT)– a process in which bacteria essentially trade resistance genes via plasmids or integrons, acting like a biological software update.

Risk Factors for Multidrug-Resistant Organisms Infections in ICU Patients

Not every ICU patient is at the same risk. The risk of multidrug-resistant organism infection depends on the patient’s baseline health status and the level of invasiveness of the medical care provided. Key risk factors include the following: 

  • Invasive Medical Devices: Central venous catheters, urinary catheters, and mechanical ventilation tubes disrupt the body’s natural skin and mucosal barriers.
  • Prior Treatment History: Long ICU stay and prior extensive exposure to broad-spectrum antibiotics.
  • Patient Vulnerability: Severe underlying comorbidities, advanced age, trauma, and immunocompromised state.

Transmission and Sources of Multidrug-Resistant Organisms in Hospitals

 MDROs travel through hospitals on pathways. Understanding these vectors helps contain them: 

  • The Patient Microbiome (Colonization): Patients may be colonized with MDROs in their gut or on their skin without symptoms and serve as an asymptomatic reservoir.
  • Healthcare Workers: The primary means of transmission for temporary bacteria is from one patient to another via unwashed hands or contaminated medical equipment (eg, stethoscopes). 
  • ICU Environment: Multidrug-Resistant Organisms like Acinetobacter are highly resilient and can live for weeks on bedrails, keyboards, and medical carts, forming tough biofilms.

Clinical Impact and Outcomes of Multidrug-Resistant Organisms Infections

MDROs have serious clinical consequences. When front-line antibiotics fail, clinicians are forced to turn to suboptimal, more toxic second-line drugs. This delay in effective therapy directly leads to the following:

  • Skyrocketing Mortality: Attributable mortality rates are far higher than susceptible infections (e.g., VRE or resistant Acinetobacter vs. susceptible counterparts). 
  • Compounded Complications: Higher frequencies of renal failure, prolonged mechanical ventilation, and septic shock.
  • Healthcare Burden: Long stays in the ICU are a huge financial burden to the patient and the healthcare facility.

Diagnosis and Laboratory Detection of Multidrug-Resistant Organisms

Speed is everything in an MDRO.

Traditional Cultures: The lab grows samples of sputum, blood, or urine to look for exact phenotypic drug resistance. This is very accurate, but it can take 48 to 72 hours.

Rapid Molecular Testing: ICUs today use Polymerase Chain Reaction (PCR) tests and next-generation sequencing (NGS). These tools identify specific resistance genes (such as blaKPC or mecA) in a matter of hours, enabling clinicians to isolate patients and adjust therapy significantly more quickly.

Treatment and Antibiotic Management of MDRO Infections

Treating an MDRO infection requires a calculated, sometimes creative, approach to pharmacology:

  • Targeted New Agents: New combination agents like meropenem/vaborbactam, ceftazidime/avibactam, or cefiderocol are employed for severe Gram-negative resistance.
  • Last-Resort and Combination Therapy: Pan-drug-resistant strains often lead clinicians to use older, more toxic drugs such as colistin or to use multi-drug combinations (e.g., mixing carbapenems, sulbactam, and colistin) to achieve a synergistic killing effect.

Infection Control and Prevention Strategies for Multidrug-Resistant Organisms in ICU

A multimodal defense system is required to prevent the spread of MDROs:

  • Proper hand hygiene: The foundation of infection control in hospitals.
  • Contact Precautions: Immediately place colonized/infected patients in isolation. Staff must wear gowns and gloves.
  • Advanced Environmental Cleaning: Use of state-of-the-art technologies such as Ultraviolet-C (UV-C) light-disinfecting robots and hydrogen peroxide nebulizers to eliminate hard-to-reach biofilms from ICU surfaces.
  • Decontamination Protocols: Daily bathing with chlorhexidine gluconate (CHG) reduces skin colonization of dangerous pathogens such as MRSA and VRE in ICU patients significantly.

Antibiotic Stewardship Programs in ICU Settings

Antibiotic stewardship programs act as the logical defense against resistance. Since the overuse of broad-spectrum antibiotics directly accelerates bacterial mutations, ASPs focus on “antibiotic-sparing” strategies. Key tactics include: 

  • Empiric Guidelines: Standardizing initial treatment based on strictly monitored, local hospital antibiograms. 
  • Rapid De-escalation: Shifting a patient from a broad, heavy-hitting antibiotic to a narrow, target-oriented drug as soon as lab culture results are available. 
  • Strict Stop Orders: Aggressively stopping antibiotic courses if an infection is ruled out or when a defined treatment window closes.

Challenges and Limitations in Managing Multidrug-Resistant Organisms Infections

Despite tight protocols, hospitals are experiencing major bottlenecks. Medicine is running out of options after a historic 30-year drought in the development of entirely new classes of antibiotics. In addition, last-resort drugs such as colistin have high nephrotoxicity, so doctors are forced to choose between curing an infection and damaging organs. The added complexity is that ICU workflow is a real thing, and sometimes emergencies arise that will break the rules of isolation and hygiene.

Guidelines and Protocols for Multidrug-Resistant Organisms Control (CDC, WHO)

The global health organizations give a standardized framework for dealing with MDROs:

  • The World Health Organization (WHO) emphasizes global surveillance, supports the Global Antimicrobial Resistance and Use Surveillance System (GLASS), and publishes core recommendations for structural hospital hygiene. 
  • Centers for Disease Control and Prevention (CDC): A very operational blueprint for U.S. hospitals. This includes clear containment strategies for emerging threats (e.g., Candida auris or carbapenem-resistant Enterobacteriaceae), specific definitions for monitoring MDRO cases, and requirements for institutional stewardship programs.

Conclusion

The control of MDROs in the ICU is no longer simply a medical problem but rather a complex and systemic challenge. To combat these tough pathogens requires a concerted effort: cutting-edge molecular diagnostics, rigorous hand hygiene, touchless environmental disinfection technologies, and aggressive antibiotic stewardship. Looking ahead, it will be essential to retain our remaining antimicrobial armamentarium while adding precise, targeted therapies to safeguard vulnerable critically ill patients.

References

  1. Antimicrobial Resistance Collaborators. (2022, February 12). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629-655. 10.1016/S0140-6736(21)02724-0
  2. Bharadwaj, A., Rastogi, A., Pandey, S., Gupta, S., & Sohal, J. S. (2022, September 05). Multidrug-Resistant Bacteria: Their Mechanism of Action and Prophylaxis. BioMed Research International, 1-17. 10.1155/2022/5419874
  3. Borg, M. A., Camilleri, L., & Waisfisz, B. (2012, August). Understanding the epidemiology of MRSA in Europe: do we need to think outside the box? Journal of Hospital Infection, 81(4), 251-256. 10.1016/j.jhin.2012.05.001
  4. Geng, S., Tang, Q., & Shi, N. (2025, September 29). Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections. Frontiers in Pharmacology, 16. 10.3389/fphar.2025.1653424
  5. Hang, Y., Zhang, J., Zhang, H. Z., Zhang, X. Y., & Wang, Y. M. (2022, February 26). Multidrug-resistant organisms in intensive care units and logistic analysis of risk factors. World Journal of Clinical Cases, 10(6), 1795-1805. 10.12998/wjcc.v10.i6.1795
  6. Munita, J. M., & Arias, C. A. (2016, April 08). Mechanisms of Antibiotic Resistance. Microbiology Spectrum, 3(2). 10.1128/microbiolspec.vmbf-0016-2015
  7. National Center for Biotechnology Information. (2020). Infections Due to Other Multidrug-Resistant Organisms—Making Healthcare Safer III. Agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK555533/
  8. Riley, M. M.-S. (2019, August). The Rising Problem of Multidrug-Resistant Organisms in Intensive Care Units. Critical Care Nurse, 39(5), 48-55. 10.4037/ccn2019773
  9. Terkimbi, S. D., Maduabuchi, P. A., Mwandah, D. C., Vandu, C. D., B, A. A., Paul-Chima, U. O., Dangana, R. S., & Mujinya, R. (2025, August 12). Molecular Mechanisms of Antimicrobial Resistance in Infectious Diseases: Advances in Therapeutic Strategies and Public Health Interventions. F1000Research, 14, 783. 10.12688/f1000research.167514.1
  10. Tosi, M., Roat, E., Biasi, S. D., Munari, E., Venturelli, S., Coloretti, I., Biagioni, E., Cossarizza, A., & Girardis, M. (2018, December). Multidrug-resistant bacteria in critically ill patients: a step further in antibiotic therapy. Journal of Emergency and Critical Care Medicine, 2, 103. 10.4037/ccn2019773
  11. World Health Organization. (2023, November 21). Antimicrobial resistance. World Health Organization (WHO). Retrieved June 6, 2026, from https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

About Author

Photo of author

Monika Joshi

Monika Joshi is a registered nurse with an experience in critical care, infectious diseases, and community health. She holds a Bachelor's degree in Nursing and has served in intensive care units at leading hospitals in Nepal, including Kathmandu Medical College, Seti Provincial Hospital, and Sukraraj Tropical and Infectious Disease Hospital. Her clinical expertise includes patient assessment, critical care monitoring, ventilator management, emergency response, infection prevention, and multidisciplinary patient care. In addition to hospital practice, Monika has worked as a field researcher at the Nepal Health Research Council, contributing to nationwide public health research projects, including surveys on access to assistive technologies using the World Health Organization's Rapid Assistive Technology Assessment (rATA) tool. Her background in community health nursing has also involved health education, disease prevention, immunization programs, and outreach services for vulnerable populations. Monika has completed professional training in Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), Primary Trauma Care (PTC), and critical care management of COVID-19. She is particularly interested in infectious diseases, critical care nursing, public health, and patient education.